1. Home
  2. PROV vs KPTI Comparison

PROV vs KPTI Comparison

Compare PROV & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PROV
  • KPTI
  • Stock Information
  • Founded
  • PROV 1956
  • KPTI 2008
  • Country
  • PROV United States
  • KPTI United States
  • Employees
  • PROV N/A
  • KPTI N/A
  • Industry
  • PROV Savings Institutions
  • KPTI Biotechnology: Pharmaceutical Preparations
  • Sector
  • PROV Finance
  • KPTI Health Care
  • Exchange
  • PROV Nasdaq
  • KPTI Nasdaq
  • Market Cap
  • PROV 98.1M
  • KPTI 102.4M
  • IPO Year
  • PROV 1996
  • KPTI 2013
  • Fundamental
  • Price
  • PROV $15.14
  • KPTI $5.62
  • Analyst Decision
  • PROV Hold
  • KPTI Strong Buy
  • Analyst Count
  • PROV 2
  • KPTI 6
  • Target Price
  • PROV $16.25
  • KPTI $22.17
  • AVG Volume (30 Days)
  • PROV 5.9K
  • KPTI 111.5K
  • Earning Date
  • PROV 10-28-2025
  • KPTI 11-03-2025
  • Dividend Yield
  • PROV 3.67%
  • KPTI N/A
  • EPS Growth
  • PROV N/A
  • KPTI N/A
  • EPS
  • PROV 0.90
  • KPTI N/A
  • Revenue
  • PROV $39,823,000.00
  • KPTI $142,530,000.00
  • Revenue This Year
  • PROV $4.14
  • KPTI $4.87
  • Revenue Next Year
  • PROV $3.70
  • KPTI $9.20
  • P/E Ratio
  • PROV $16.98
  • KPTI N/A
  • Revenue Growth
  • PROV 0.07
  • KPTI N/A
  • 52 Week Low
  • PROV $12.98
  • KPTI $3.51
  • 52 Week High
  • PROV $16.70
  • KPTI $13.20
  • Technical
  • Relative Strength Index (RSI)
  • PROV 53.67
  • KPTI 45.34
  • Support Level
  • PROV $14.95
  • KPTI $5.31
  • Resistance Level
  • PROV $15.50
  • KPTI $6.50
  • Average True Range (ATR)
  • PROV 0.37
  • KPTI 0.41
  • MACD
  • PROV 0.01
  • KPTI 0.00
  • Stochastic Oscillator
  • PROV 68.75
  • KPTI 36.25

About PROV Provident Financial Holdings Inc.

Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. It is a financial services company committed to serving consumers and small to mid-sized businesses in the Inland Empire region of Southern California. Its business activities consist of community banking, investment services and trustee services for real estate transactions. The group operates in Bank segment that include attracting deposits, offering banking services and originating and purchasing single-family, multi-family, commercial real estate, construction and, to a lesser extent, other mortgage, commercial business and consumer loans. Its evenues are derived from interest earned on its loan and investment portfolios, and fees generated through its community banking activities.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: